The Independent NHS watchdog to review evidence on two pioneering Alzheimer’s drugs
Donanemab and lecanemab were licensed for use in the UK in 2024 but were not made available on the NHS after Nice deemed their benefits “too small” to justify the cost
Donanemab and lecanemab were licensed for use in the UK in 2024 but were not made available on the NHS after Nice deemed their benefits “too small” to justify the cost